Effectiveness of a stand-alone aftercare program for drug-involved offenders.

A study was made of the effectiveness of an aftercare program operating in conjunction with area outpatient drug free treatment programs while organizationally independent of those programs. Parolees and probationers mandated to treatment were assigned to aftercare on the basis of residence in the catchment areas in which aftercare facilities were located (n = 32) and randomly to aftercare (n = 62) and control (n = 51) when not a resident in a catchment area. No outcome differences were found between aftercare groups based on proximity to facility. At 6 months postbaseline the combined aftercare group showed significantly lower levels of criminal activity and frequent drug use as compared to controls. At 12 months postbaseline there was an attenuation of group differences with only tendencies toward significance obtained for lower levels of frequent drug use by the aftercare group. The findings are discussed in terms of the relevance of community variables for programming and for understanding long-term treatment outcomes.

Purpuric phototherapy-induced eruption in transfused neonates: relation to transient porphyrinemia.

OBJECTIVE: Blue light phototherapy is commonly administered to neonates as treatment of indirect hyperbilirubinemia, often in conjunction with blood transfusions to treat hemolytic anemia. We observed a distinctive cutaneous complication of phototherapy in six neonates with hyperbilirubinemia. METHODOLOGY: We studied the clinical and histologic characteristics of the eruption, as well as the porphyrin levels in affected neonates. Five of the patients had erythroblastosis fetalis; the other had profound anemia from twin-twin transfusion. All of the neonates developed purpuric patches at sites of maximal exposure to the phototherapy lights, with dramatic sparing at shielded sites within 24 hours after initiation of the phototherapy. On discontinuation of phototherapy, all eruptions cleared within 1 week. Examination of skin biopsy sections showed purpura without significant inflammation or keratinocyte necrosis. Plasma porphyrins (copro- and proto-) were elevated in the two patients in which they were assessed. CONCLUSIONS: The distribution of the eruption in areas exposed to light and presence of circulating porphyrins suggest that porphyrinemia may underlie the light-induced purpuric eruption. Additional studies will be required to determine definitively the mechanisms of both the purpuric phototherapy-induced eruption and the development of increased blood porphyrin levels in these transfused neonates.

Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks' gestation.

OBJECTIVE: To determine if an additive effect exists between antenatal corticosteroid administration and postnatal surfactant therapy in the prevention of respiratory distress syndrome (RDS) in preterm infants. METHODS: A randomized, double-blind trial was conducted from April 1990 to June 1994, in which dexamethasone (5 mg every 12 hours for a total of four doses) or saline was given to women at risk for delivery at 24-29 weeks' gestation. At birth, prophylactic surfactant was administered to all study infants. Main outcome measures were RDS occurrence and severity. Secondary clinical end points included bronchopulmonary dysplasia, pneumothorax, patent ductus arteriosus, necrotizing enterocolitis, retinopathy, intraventricular hemorrhage, and death. RESULTS: Seventy-five of the 124 randomized subjects delivered 96 infants within the studied gestational age range (dexamethasone, n = 54; placebo, n = 42). Similar maternal demographics and obstetric complications were noted between study groups. A greater population of infants were delivered from multi-fetal gestations in the dexamethasone cohort (26 of 54 versus 12 of 42 newborns; P = .05). There were no significant differences in the occurrence or severity of RDS between the dexamethasone and placebo infants (none or mild, 67 versus 67%; moderate, 24 versus 26%; severe, 9 versus 7%, respectively), or differences in any of the secondary clinical outcomes. The study size was sufficient to exclude a 50% reduction in RDS incidence as a consequence of dexamethasone exposure. An analysis restricted to singletons (dexamethasone, n = 28; placebo, n = 30) revealed similar overall occurrence of intraventricular hemorrhage (12 of 28 versus ten of 30; P = .63), but significantly fewer grade 3 and 4 intraventricular hemorrhages in dexamethasone-exposed neonates (two of 12 versus six of ten; P = .048). CONCLUSION: Antenatal dexamethasone does not appear to decrease the incidence or severity of RDS in surfactant-treated infants delivered at 24-29 weeks' gestation, but may be associated with reduced severity of intraventricular hemorrhages in surfactant-treated singletons in this gestational age range.

A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome.

OBJECTIVE: To compare the efficacy and safety of two surfactant preparations in the treatment of respiratory distress syndrome (RDS). METHODS: We conducted a randomized, masked comparison trial at 21 centers. Infants with RDS who were undergoing mechanical ventilation were eligible for treatment with two doses of either a synthetic (Exosurf) or natural (Infasurf) surfactant if the ratio of arterial to alveolar partial pressure of oxygen was less than or equal to 0.22. Crossover treatment was allowed within 96 hours of age if severe respiratory failure (defined as two consecutive arterial/alveolar oxygen tension ratios < or = 0.10) persisted after two doses of the randomly assigned surfactant. Four primary outcome measures of efficacy (the incidence of pulmonary air leak (< or = 7 days); the severity of RDS; the incidence of death from RDS; and the incidence of survival without bronchopulmonary dysplasia (BPD) at 28 days after birth) were compared by means of linear regression techniques. RESULTS: The primary analysis of efficacy was performed in 1033 eligible infants and an analysis of safety outcomes in the 1126 infants who received study surfactant. Preentry demographic characteristics and respiratory status were similar for the two treatment groups, except for a small but significant difference in mean gestational age (0.5 week) that favored the infasurf treatment group. Pulmonary air leak (< or = 7 days) occurred in 21% of Exosurf- and 11% of infasurf-treated infants (adjusted relative risk, 0.53; 95% confidence interval, 0.40 to 0.71; p < or = 0.0001). During the 72 hours after the initial surfactant treatment, the average fraction of inspired oxygen (+/-SEM) was 0.47 +/- 0.01 for Exosurf- and 0.39 +/- 0.01 for infasurf-treated infants (difference, 0.08; 95% confidence interval, 0.06 to 0.10; p < 0.0001); the average mean airway pressure (+/-SEM) was 8.6 +/- 0.1 cm H2O; for Exosurf- and 7.2 +/- 0.1 cm H2O for Infasurf-treated infants (difference, 1.4 cm H2O; 95% confidence interval, 1.0 to 1.8 cm H2O; p < 0.0001). The incidences of RDS-related death, total respiratory death, death to discharge, and survival without bronchopulmonary dysplasia at 28 days after birth did not differ. The number of days of more than 30% inspired oxygen and of assisted ventilation, but not the duration of hospitalization, were significantly lower in Infasurf-treated infants. CONCLUSION: Compared with Exosurf, Infasurf provided more effective therapy for RDS as assessed by significant reductions in the severity of respiratory disease and in the incidence of air leak complications.

Amniotic fluid lamellar body count: a rapid and reliable fetal lung maturity test.

OBJECTIVE: To evaluate the lamellar body count as a predictor of fetal lung maturity. METHODS: We conducted a prospective clinical outcome study. Amniocentesis was performed for evaluation of fetal lung maturity status within 72 hours of delivery in 130 patients. A lamellar body count was performed on each specimen, and a lecithin-sphingomyelin ratio and lung phospholipid profile were performed when possible (insufficient sample or contamination in eight cases). Each infant was evaluated for evidence of respiratory distress syndrome (RDS). RESULTS: A lamellar body count exceeding 30,000/microL predicted pulmonary maturity correctly in all cases (negative predictive value 1.00). All 16 cases of RDS had counts of 30,000/microL or less. If the lamellar body count was less than 10,000/microL, the positive predictive value for RDS was 67%, and the likelihood of a mature result from chromatographic phospholipid analysis was low (one of 14, 7%). Values between 10,000-30,000/microL indicated intermediate risk (four of 39, 10%) for developing RDS. Phospholipid analysis indicated fetal lung maturity in 35 of 39 (90%) cases with lamellar body counts in the intermediate risk range. CONCLUSIONS: The lamellar body count compares favorably with traditional phospholipid testing in the prediction of fetal lung maturity. Phospholipid analysis is not needed with lamellar body counts greater than 30,000/microL or less than 10,000/microL, but may be of benefit for values in the intermediate risk range. Advantages of this test include speed, objectivity, small sample volume required, and universal availability of instrumentation.

Radioimmunodetection of colorectal carcinoma with 111In-labelled monoclonal antibody IVP ZCE 025 (a tissue culture-produced anti-CEA MAb).

The aims of this prospective, nonrandomized phase I/II study were to evaluate (1) the safety and (2) the detection rate of tissue culture-derived, 111In-labelled anti-CEA monoclonal antibody IVP ZCE 025 in patients with primary, metastatic and occult colorectal carcinomas. 111In-IVP ZCE 025 imaging correctly identified 31 of 37 primary colorectal carcinomas, 10 of 19 hot liver metastases, 11 of 16 distant metastases and seven of seven local tumour recurrences. Previously unsuspected tumours were detected by IVP ZCE 025 imaging in 11 of 34 patients. The scans were also true negative in four patients. The overall performance characteristics of IVP ZCE 025 at monoclonal antibody doses of 1.0-5.0 mg were comparable to those obtained with 40.0 mg ascites-produced ZCE 025. No clinical or biochemical adverse reactions were encountered in the 61 patients entered into this study.

Perinatal factors influencing survival at twenty-four weeks' gestation.

OBJECTIVE: Our objective was to identify those obstetric and neonatal factors associated with survival in infants delivered at 24 weeks' gestation. STUDY DESIGN: The obstetric and pediatric data bases from the two hospitals in our perinatal center were examined to ascertain all infants delivered between 1987 and 1989 whose gestational age was 24 weeks to 24 weeks 6 days. This time interval was chosen to coincide with the introduction of prophylactic exogenous surfactant. Data were abstracted from the maternal antepartum and intrapartum records and the neonatal records, with specific attention to objective risk factors related to survival. RESULTS: Forty-five pregnant patients were identified and delivered of 52 infants. Seventeen newborn infants survived (33%). Univariate comparisons between survivors and nonsurvivors revealed more aggressive intrapartum care in the former cohort as represented by the frequencies of internal fetal heart rate monitoring (p = 0.005), maternal oxygen therpay (p = 0.003), and maternal position change to remediate decelerations (p = 0.001). Planned exclusion of cesarean delivery was more common in those pregnancies that ended in fetal or neonatal death (29/35 vs 7/17; p = 0.006). Although a greater proportion of infants delivered by cesarean section survived (6/11 vs 11/41), this difference was not significant (p = 0.17). With the use of logistic regression, the best predictor of survival was gestational age at delivery. Neonatal care was more aggressive among survivors, as measured by the relative frequencies of resuscitation and surfactant administration. Respiratory distress syndrome was either absent (n = 6) or mild (n = 6) in a majority of the survivors, and respiratory insufficiency was the major cause of neonatal death. CONCLUSION: Perinatal outcome at 24 weeks' gestation appears most dependent on gestational age at delivery. The intensity of intrapartum care and neonatal support, as well as clinical biases regarding survivability, may also influence outcome.

Antenatal steroid therapy before 33 weeks' gestation.

OBJECTIVE: The purpose of this study was to determine those factors influencing contemporary antenatal steroid use in pregnancies delivered prior to 33 weeks of gestation. METHOD: We analyzed the clinical circumstances of 86 consecutive patients who delivered prior to 33 weeks of gestation and compared to 20 women who received dexamethasone prior to delivery with the remaining 66 untreated cases. RESULT: Known risk factors for preterm delivery (e.g. prior preterm birth, n = 17; prior admission and tocolysis during the index pregnancy, n = 15) did not discriminate between treated and untreated subsets. Premature membrane rupture (3/20 vs. 34/66; P < 0.01) and documented preterm labor (1/20 vs. 23/66 P < 0.01) were more common in the untreated cohort and a shorter mean interval from admission to delivery was also observed (2.8 vs 11.2 days). However, a full course of steroids would have been possible in 22/66 untreated women, since delivery was delayed for at least 36 h in these patients. CONCLUSION: These observations reflect the fact that many preterm births cannot be anticipated, even among hospitalized patients. We would therefore suggest that universal steroid treatment be considered for all women with documented preterm labor prior to 33 weeks of gestation. Initiation of steroid therapy at the referral center, (prior to maternal transport) should also be considered. Since both premature membrane rupture and early gestational age (24-28 weeks') confounded many of these cases, steroid use in patients with these circumstances should be reevaluated.

Neurodevelopmental outcome in infants with bronchopulmonary dysplasia.

It appears that the survivor of BPD is at risk for neurodevelopmental compromise but not necessarily to any greater extent than are prematurely born infants in general. What appears to be true is that as the neonatal course becomes more complicated, and the birth weight drops, the risk increases. If a BPD survivor sustains a moderate to severe IVH, particularly if accompanied by periventricular leukomalacia, the risk of significant handicap increases substantially. Effects of socioeconomic status (SES) are also important, and become more evident over time with a direct correlation between SES and outcome. Maximizing the environmental conditions while in the special care nursery, and reducing stress on the infant during the illness, may help to reduce risk of a compromised developmental outcome in the survivors. Careful monitoring of oxygen saturation postdischarge may similarly have a positive effect on outcome. Although direct comparability among studies is not possible, it appears that most reports suggest about half the survivors are free of any handicapping condition at follow-up, and about half are either moderately or severely impaired. Cerebral palsy is the most frequently reported handicapping condition. Since the presence or absence of significant IVH is not consistently reported across studies, it is not possible to know if infants who subsequently develop CP sustained a bleed, in addition to BPD, in the neonatal period. In studies in which this is more carefully delineated, that appears to be the case. In studies in which infants with significant hemorrhage were either excluded or dropped out, no survivors with cerebral palsy are reported. Approximately 4% of survivors across all studies reviewed were blind as a result of severe retinopathy of prematurity. Several studies excluded infants who developed significant ROP from their follow-up, so this percentage may be an underestimate of the actual incidence across all BPD survivors. With a greater number of gestationally younger infants surviving, this is one area of handicap that may increase in the years to come. Not all studies report on the presence of sensorineural hearing loss in survivors, but there is the suggestion this may occur perhaps in up to 4% of survivors. This is an area that future research should address. For infants who fall in the moderately handicapped category, typically defined as more than one standard deviation below the mean on a standardized developmental examination, that rating may change over time in either direction.(ABSTRACT TRUNCATED AT 400 WORDS)

The perinatal management of central nervous system anomalies.

The diagnosis, proper evaluation, and treatment of a CNS anomaly requires the participation of many subspecialists and support personnel. The outcome can be favorably modified through the choice of elective termination, aggressive or passive perinatal intervention, and the 24-hour availability of neurosurgical expertise. At the conclusion of the pregnancy, accurate and informative counseling also should be provided. Although these discussions need not take place immediately, review of the final diagnosis, its risk of recurrence, and the appropriate screening for subsequent pregnancy should be included.

Impact of antenatal dexamethasone administration on respiratory distress syndrome in surfactant-treated infants.

Neonatal lung disease is primarily responsible for the perinatal morbidity and mortality associated with preterm birth. Recently exogenous surfactant replacement therapy has been used to prevent or treat respiratory distress syndrome. As part of a multicenter, preventive trial between February 1986 and December 1988 using calf-lung surfactant extract, we treated 147 infants with single dose calf-lung surfactant extract. We analyzed this experience to evaluate the possibility that antenatal steroids may be additive (with calf-lung surfactant extract) in reducing both the incidence and severity of respiratory distress syndrome. Although a reduction in the incidence of respiratory distress syndrome was observed among the 33 neonates exposed to antenatal dexamethasone when compared with the 114 infants given calf-lung surfactant extract alone, the difference was not significant (37.7% vs. 24.2% p = 0.15). However, comparison of neonatal subsets previously shown to benefit most from steroid use revealed an additive effect between calf-lung surfactant extract and dexamethasone in reducing both the incidence and severity of respiratory distress syndrome. Of the 99 singleton pregnancies, only 2 of 16 infants treated with calf-lung surfactant extract and dexamethasone developed respiratory distress syndrome, compared with the 33 of 83 calf-lung surfactant extract cases (p less than 0.05). A similar reduction was observed in infants between 28 and 32 weeks' gestation (calf-lung surfactant extract, 21 of 79 vs. calf-lung surfactant extract and dexamethasone, 0 of 24; p less than 0.05). A reduction in disease severity was observed in male offspring (moderate or severe respiratory distress syndrome only; 22 of 63 vs. 2 of 22; p less than 0.05). Potential confounding variables (e.g., gestational age at birth, birth weight, exposure to tocolytics before delivery, fetal pH at birth) were similar in all comparisons. We conclude that an additive effect between dexamethasone and calf-lung surfactant extract is observed in selected cases. It may therefore be appropriate to maximize antenatal steroid use in centers where exogenous surfactant is available.

Fetal ear length.

A prenatal standard for ear length was developed from ultrasonic images of 180 normal subjects. Length increased from about 6 mm at 15 weeks to 33 mm at term and was well fit by linear regression (r2 = .96). Short ears (greater than or equal to 1.5 SD below gestational age average) were associated strongly, and specifically, with chromosomal disorders.

Fetal hyaloid artery: timing of regression with US.

Large-aperture, dynamically focused ultrasonic imaging permits noninvasive, anatomic study of the eye at the millimeter level in the second and third trimesters of pregnancy. The authors report their observations of the hyaloid artery in 210 of 219 fetuses examined with this technique. This vessel is seen in fetuses of 20 weeks gestational age or less and regresses spontaneously at the start of the third trimester. The 210 subjects included 100 who were examined at gestational ages of 16-32 weeks or more and 85 healthy fetuses and 25 with pathologic findings at birth who were examined at 34 weeks gestational age to term. The presence of the hyaloid artery in the mid third trimester was uncommon in healthy subjects (less than 1%) and was not seen in any beyond 29.9 weeks gestational age. However, in nine of the 25 fetuses with abnormalities (five with trisomy syndromes), the vessel was seen at 30.8-36.8 weeks gestational age. The temporarily delayed regression of the hyaloid artery may occur with trisomy 21 syndrome and other forms of retarded brain development.

Delivery room management of meconium staining of the amniotic fluid and the development of meconium aspiration syndrome.

A 1-year prospective survey of obstetric and pediatric management of meconium staining of the amniotic fluid in 464 patients was undertaken. Pharyngeal suctioning before delivery was performed using bulb syringe (N = 130), De Lee suction catheter (N = 186), or both (N = 98); endotracheal intubation after delivery was also done in 413 instances. Using any of the three suctioning techniques, no differences were seen in Apgar scores, respiratory rates, presence or absence of meconium on or below the vocal cords, or development of meconium aspiration syndrome (MAS). If meconium was present on the vocal cords, it was present below the vocal cords in 76% of the cases. If no meconium was visualized, it was found below the vocal cords in only 7% of the cases. Of the 142 infants with meconium below the vocal cords, 10% developed MAS and all 14 survived.

Umbilical artery catheterization complicated by multiple mycotic aortic aneurysms.

A premature infant had three pseudoaneurysms of the thoracic and abdominal aorta secondary to umbilical artery catheterization and sepsis. The infant had septicemia as the direct result of bacterial contamination of an umbilical artery catheter with Staphylococcus aureus. The thoracic pseudoaneurysm caused massive hemothorax and the infant's death. The upper abdominal aortic aneurysm developed at the level of the renal arteries and caused decreased left renal blood flow and renal hypoplasia. The lower abdominal aneurysm involved the right iliac artery and was complicated by mural thrombosis and ischemia of the right leg. To our knowledge, this is the first published case of multiple mycotic aortic aneurysms after umbilical artery catheterization.

Fetal lung development: compressibility as a measure of maturity.

Fetal lung maturation involves a number of separate developmental processes. An ultrasonic technique is reported for grading the dynamic behavior of the right middle lobe or lingula in the second or third trimesters on ultrasound (US) study. Fetal lungs are stiff initially. Lung compressibility during diastole is typical after 36 weeks' gestational age, when phospholipid profiles of the amniotic fluid also indicate lung-tissue maturity. Compressibility also occurs earlier in the third trimester and has indicated, in preliminary observations on a small subgroup of infants delivered prematurely, a low risk of subsequent neonatal respiratory distress syndrome. High-speed magnification US study of fetal lung compressibility can be used to evaluate fetal lung development, possibly independently of gestational age and of conventionally measured lecithin/sphingomyelin values in amniotic fluid.